India], July 28: Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks ‘World ART (Assisted Reproductive ...

MSFT, BABA, and MRK headline today's top analyst picks, with AI, global e-commerce, and oncology driving mixed growth stories ...

MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

Also in today’s newsletter, EU warns Europe’s roads unfit for war, UBS currency derivatives and Botswana’s push on De Beers ...

Designed by Sylvia Richards, the mass-timber addition to Adimab's Lebanon campus is sensitive to the lushly forested wetland ...

However, Merck & Co., Inc. (NYSE:MRK)’s shares have lost 16% year-to-date, primarily on the back of weak earnings reports and worries about the firm’s GARDASIL drug.

Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find out why I rate MRK a Buy.

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s best ...

The ongoing Phase I/IIa study (NCT04725331) is a multicenter, open label, dose-escalation study evaluating BT-001 as a single agent and in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) ...

"Morphoceuticals is building a platform that has the potential to transform human health,” said Pomerantz. "I am proud to ...

Biogen said it intends to invest an additional $2 billion to expand operations at its largest manufacturing facilities within North Carolina’s Research Triangle Park (RTP).